Hikma Pharmaceuticals Public annual free cash flow per share
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Free Cash Flow Per Share Growth & History (HIK)
Hikma Pharmaceuticals Public's free cash flow per share was $1.08 for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.08 | -$0.72 | −39.90% |
| 2024 | 2024-12-31 | $1.80 | -$0.19 | −9.39% |
| 2023 | 2023-12-31 | $1.99 | $0.24 | +13.45% |
| 2022 | 2022-12-31 | $1.75 | -$0.38 | −17.95% |
| 2021 | 2021-12-31 | $2.13 | $0.90 | +72.56% |
| 2020 | 2020-12-31 | $1.24 | — | — |
Hikma Pharmaceuticals Public free cash flow per share trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's free cash flow per share decreased from $1.24 to $1.08, a change of -$0.16.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...